These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 34520702)

  • 1. Opioid treatment programs, telemedicine and COVID-19: A scoping review.
    Chan B; Bougatsos C; Priest KC; McCarty D; Grusing S; Chou R
    Subst Abus; 2022; 43(1):539-546. PubMed ID: 34520702
    [No Abstract]   [Full Text] [Related]  

  • 2. Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?
    Nunes EV; Levin FR; Reilly MP; El-Bassel N
    J Subst Abuse Treat; 2021 Mar; 122():108196. PubMed ID: 33221125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in the delivery of medications for opioid use disorder during hospitalization by racial categories: A retrospective cohort analysis.
    Priest KC; King CA; Englander H; Lovejoy TI; McCarty D
    Subst Abus; 2022; 43(1):1251-1259. PubMed ID: 35670778
    [No Abstract]   [Full Text] [Related]  

  • 5. The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): A nationwide Veterans Health Administration cohort study.
    Livingston NA; Davenport M; Head M; Henke R; LeBeau LS; Gibson TB; Banducci AN; Sarpong A; Jayanthi S; Roth C; Camacho-Cook J; Meng F; Hyde J; Mulvaney-Day N; White M; Chen DC; Stein MD; Weisberg R
    Drug Alcohol Depend; 2022 Dec; 241():109678. PubMed ID: 36368167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the impact of social distancing measures implemented during COVID-19 pandemic on medications for opioid use disorder in West Virginia.
    Haggerty T; Khodaverdi M; Dekeseredy P; Wood N; Hendricks B; Peklinsky J; Sedney CL
    J Subst Abuse Treat; 2022 May; 136():108687. PubMed ID: 34903397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Access to Medications for Opioid Use Disorder and Associated Factors Among Adolescents and Young Adults: A Systematic Review.
    Pilarinos A; Bromberg DJ; Karamouzian M
    JAMA Pediatr; 2022 Mar; 176(3):304-311. PubMed ID: 34870707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impacts of the COVID-19 pandemic on enrollment in medications for opioid use disorder (MOUD) in Vancouver, Canada: An interrupted time series analysis.
    Eugenia Socias M; Choi JC; Fairbairn N; Johnson C; Wilson D; Debeck K; Brar R; Hayashi K
    Int J Drug Policy; 2023 Aug; 118():104075. PubMed ID: 37271070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioid use disorder incidence and treatment among incarcerated pregnant women in the United States: results from a national surveillance study.
    Sufrin C; Sutherland L; Beal L; Terplan M; Latkin C; Clarke JG
    Addiction; 2020 Nov; 115(11):2057-2065. PubMed ID: 32141128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mobile Telemedicine for Buprenorphine Treatment in Rural Populations With Opioid Use Disorder.
    Weintraub E; Seneviratne C; Anane J; Coble K; Magidson J; Kattakuzhy S; Greenblatt A; Welsh C; Pappas A; Ross TL; Belcher AM
    JAMA Netw Open; 2021 Aug; 4(8):e2118487. PubMed ID: 34448869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review.
    Krawczyk N; Fawole A; Yang J; Tofighi B
    Addict Sci Clin Pract; 2021 Nov; 16(1):68. PubMed ID: 34774106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Massachusetts Justice Community Opioid Innovation Network (MassJCOIN).
    Evans EA; Stopka TJ; Pivovarova E; Murphy SM; Taxman FS; Ferguson WJ; Bernson D; Santelices C; McCollister KE; Hoskinson R; Lincoln T; Friedmann PD;
    J Subst Abuse Treat; 2021 Sep; 128():108275. PubMed ID: 33483222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees.
    Hammerslag LR; Mack A; Chandler RK; Fanucchi LC; Feaster DJ; LaRochelle MR; Lofwall MR; Nau M; Villani J; Walsh SL; Westgate PM; Slavova S; Talbert JC
    JAMA Netw Open; 2023 Oct; 6(10):e2336914. PubMed ID: 37851446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of methamphetamine/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review.
    Frost MC; Lampert H; Tsui JI; Iles-Shih MD; Williams EC
    Addict Sci Clin Pract; 2021 Oct; 16(1):62. PubMed ID: 34635170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An examination of telehealth policy impacts on initial rural opioid use disorder treatment patterns during the COVID-19 pandemic.
    Hughes PM; Verrastro G; Fusco CW; Wilson CG; Ostrach B
    J Rural Health; 2021 Jun; 37(3):467-472. PubMed ID: 33720447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies.
    Degenhardt L; Clark B; Macpherson G; Leppan O; Nielsen S; Zahra E; Larance B; Kimber J; Martino-Burke D; Hickman M; Farrell M
    Lancet Psychiatry; 2023 Jun; 10(6):386-402. PubMed ID: 37167985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TIME TO REVISIT UNEVEN POLICY IN THE UNITED STATES FOR MEDICATION FOR OPIOID USE DISORDER DURING COVID-19.
    Pena E; Ahmed S
    Addiction; 2020 Oct; 115(10):1978-1979. PubMed ID: 32447795
    [No Abstract]   [Full Text] [Related]  

  • 18. COVID-19 and treating incarcerated populations for opioid use disorder.
    Donelan CJ; Hayes E; Potee RA; Schwartz L; Evans EA
    J Subst Abuse Treat; 2021 May; 124():108216. PubMed ID: 33288348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The COVID-19 pandemic and opioid use disorder: Expanding treatment with buprenorphine, and combining safety precautions with telehealth.
    Cales RH; Cales SC; Shreffler J; Huecker MR
    J Subst Abuse Treat; 2022 Feb; 133():108543. PubMed ID: 34210567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementation of Telemedicine Delivery of Medications for Opioid Use Disorder in Pennsylvania Treatment Programs During COVID-19.
    Poulsen MN; Santoro W; Scotti R; Henderson C; Ruddy M; Colistra A
    J Addict Med; 2023 Mar-Apr 01; 17(2):e110-e118. PubMed ID: 36129690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.